Class I basic helix-loop-helix transcription factors (E-proteins) (E-proteins)

NeuroD1 is a basic helix-loop-helix (bHLH) transcription factor that is essential for the development of the central nervous system and the endocrine pancreas (Naya et al., 1997, Genes & Development). To exert its transcriptional activity, NeuroD1 must form heterodimers with Class I bHLH proteins, collectively known as E-proteins, which include TCF3 (E2A), TCF4 (E2-2), and TCF12 (HEB) (UniProt P15923, P15884, Q99081). These heterodimers bind to E-box DNA sequences (CANNTG) to regulate genes critical for neuronal differentiation and insulin production (Huang et al., 2000, Mol Cell Biol). Dysregulation of these partners or their interaction with NeuroD1 is linked to Maturity-Onset Diabetes of the Young type 6 (MODY6) and neurodevelopmental conditions like Pitt-Hopkins syndrome (Malecki et al., 1999, Nature Genetics). While traditionally considered undruggable, the NeuroD1-E-protein interface is a subject of research for small-molecule inhibitors aimed at treating neuroendocrine tumors and metabolic diseases. Therapeutic challenges include the ubiquitous nature of E-proteins, which are also required for B-cell development and other vital processes, raising concerns about systemic toxicity (Massari & Murre, 2000, Mol Cell Biol). Current drug discovery efforts focus on identifying peptidomimetics or small molecules that can specifically disrupt the bHLH dimerization interface to modulate gene expression in a tissue-specific manner.

Other names

TCF3TCF4TCF12E2AE2-2HEBClass I bHLH proteinsTranscription factor 3Transcription factor 4Transcription factor 12BETA2-E-protein complex

The primary mechanism of action for therapeutic candidates involves the inhibition of protein-protein interaction (PPI) between NeuroD1 and its E-protein partners, thereby preventing the formation of functional heterodimers and subsequent binding to E-box DNA sequences to modulate target gene expression.